Zepbound (Tirzepatide): Treatment for Chronic Weight Loss

Zepbound is the first and only FDA-approved treatment for chronic weight management that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Who is Zepbound for?
Zepbound is indicated for adults with obesity (BMI of 30 kg/m² or greater) or those who are overweight (BMI of 27 kg/m² or greater) and have at least one weight-related condition, such as:

• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol)
• Type 2 diabetes
• Obstructive sleep apnea

Clinical Results (SURMOUNT Trials):
In clinical trials, Zepbound showed superior weight reduction results compared to placebo. By addressing the physiological drivers of weight gain—such as appetite regulation and metabolic function—Zepbound helps patients achieve and maintain substantial weight loss when combined with a reduced-calorie diet and increased physical activity.

Zepbound vs. Mounjaro: What is the Difference?

Both Zepbound and Mounjaro contain the exact same active ingredient: tirzepatide. However, they are FDA-approved for different uses.

• Zepbound is specifically labeled for Chronic Weight Management.
• Mounjaro is specifically labeled for Type 2 Diabetes.

Why the distinction matters:
Insurance companies often require the correct label to cover the medication. If you do not have diabetes but need help with weight management, Zepbound is the appropriate prescription. It works by mimicking natural hormones to signal fullness to the brain (“reducing food noise”) and slowing digestion, allowing you to feel satisfied with smaller portions.